NCT04104282

Brief Summary

To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
240

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2016

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

September 24, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 26, 2019

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 27, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 27, 2025

Completed
Last Updated

September 19, 2024

Status Verified

July 1, 2019

Enrollment Period

9.1 years

First QC Date

September 24, 2019

Last Update Submit

September 18, 2024

Conditions

Non-alcoholic Fatty Liver Disease

Keywords

Nonalcoholic fatty liver diseaseLipid dropletsPlin5

Outcome Measures

Primary Outcomes (1)

  • The severity of non-alcoholic fatty liver disease

    Evaluating by ultrasound the severity of non-alcoholic fatty liver disease

    3 months

Secondary Outcomes (1)

  • The expression of plin5

    3 months

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with was confirmed by clinical presentation, ultrasound and laboratory test. At the same time, participants who enrolled this statistical analysis without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases. (range, 18-75 years).

You may qualify if:

  • The diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.

You may not qualify if:

  • With long-term drinking history, viral hepatitis, medication history, obesity (BMI≥30), type 2 diabetes and other metabolic diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Department of Ultrasonic Medicine, The Xijing Hospital of Fourth Military Medical University

Xi'an, Shaanxi, 710032, China

RECRUITING

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System Diseases

Study Officials

  • Ming Yu, PhD, MD

    The Xijing Hospital of Fourth Military Medical University

    STUDY DIRECTOR

Central Study Contacts

Ming Yu, PhD, MD

CONTACT

15209239680huihui2807201830@163.com

Huihui Zhou, MD

CONTACT

18066896622huihui2807201830@126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2019

First Posted

September 26, 2019

Study Start

December 1, 2016

Primary Completion

December 27, 2025

Study Completion

December 27, 2025

Last Updated

September 19, 2024

Record last verified: 2019-07

Locations

CN(1)